This category of Benenefits describes various aspects related to the prevention, reduction, and understanding of virus transmission in infrastructure and the human population. It includes studies on anti-coronavirus drugs, enhanced antibacterial and antiviral properties, and rapid deployment of virus-inactivating solutions. It also covers the visualization and estimation of virus spread, indication of virus circulation in the human population, and the reduction of virus viability in indoor air. Additionally, it includes the protection against virus transmission, reduction in airborne virus concentration, and the inactivation of respiratory animal viral aerosols. Overall, this category of Benenefits focuses on the measures and mechanisms to limit, prevent, and decrease the spread of viruses in infrastructure and the wider community.